Description: MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. The company's products under development include CannEpil, which is in Phase IIb clinical trial for the treatment in children and adolescents with refectory epilepsy; CogniCann that is in Phase II clinical trial to treat dementia and Alzheimer's diseases; and ArtemiC, which is in Phase II clinical trial for the treatment COVID-19. It has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, the University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.
Home Page: mgcpharma.com.au
MXC Technical Analysis
1202 Hay Street
West Perth,
WA
6005
Australia
Phone:
61 8 6382 3390
Officers
| Name | Title |
|---|---|
| Mr. Roby Reuven Zomer | Co-Founder, CEO, MD & Exec. Director |
| Ms. Angela-Marie Graham | Group Chief Financial Officer |
| Ms. Yifat Steuer | Deputy CEO & COO |
| Mr. Amir Polak | Chief Technology Officer |
| Ms. Nicole Ann Godresse | Global Chief Sales Officer |
| Ms. Sabina Suljakovic | Head of the Quality Assurance Department |
| Dr. Nadya Lisovoder | Chief Medical Officer |
| Ms. Sasha Friedman | Deputy CEO |
| Yair Tal | Chief Information Security Officer |
| Mr. Robert Clements | Chief Commercial Officer |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 13.6799 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.9829 |
| Price-to-Sales TTM: | 4.088 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |